These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27649552)

  • 1. A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer.
    Salvucci M; Würstle ML; Morgan C; Curry S; Cremona M; Lindner AU; Bacon O; Resler AJ; Murphy ÁC; O'Byrne R; Flanagan L; Dasgupta S; Rice N; Pilati C; Zink E; Schöller LM; Toomey S; Lawler M; Johnston PG; Wilson R; Camilleri-Broët S; Salto-Tellez M; McNamara DA; Kay EW; Laurent-Puig P; Van Schaeybroeck S; Hennessy BT; Longley DB; Rehm M; Prehn JH
    Clin Cancer Res; 2017 Mar; 23(5):1200-1212. PubMed ID: 27649552
    [No Abstract]   [Full Text] [Related]  

  • 2. BCL-2 system analysis identifies high-risk colorectal cancer patients.
    Lindner AU; Salvucci M; Morgan C; Monsefi N; Resler AJ; Cremona M; Curry S; Toomey S; O'Byrne R; Bacon O; Stühler M; Flanagan L; Wilson R; Johnston PG; Salto-Tellez M; Camilleri-Broët S; McNamara DA; Kay EW; Hennessy BT; Laurent-Puig P; Van Schaeybroeck S; Prehn JHM
    Gut; 2017 Dec; 66(12):2141-2148. PubMed ID: 27663504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
    Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
    [No Abstract]   [Full Text] [Related]  

  • 4. A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic.
    Salvucci M; Rahman A; Resler AJ; Udupi GM; McNamara DA; Kay EW; Laurent-Puig P; Longley DB; Johnston PG; Lawler M; Wilson R; Salto-Tellez M; Van Schaeybroeck S; Rafferty M; Gallagher WM; Rehm M; Prehn JHM
    JCO Clin Cancer Inform; 2019 Apr; 3():1-17. PubMed ID: 30995124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
    Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
    Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of somatic mutation signatures for risk stratification and prognosis in lung and colorectal adenocarcinomas.
    Menor M; Zhu Y; Wang Y; Zhang J; Jiang B; Deng Y
    BMC Med Genomics; 2019 Jan; 12(Suppl 1):24. PubMed ID: 30704450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
    Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
    PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.
    Yang WJ; Wang HB; Wang WD; Bai PY; Lu HX; Sun CH; Liu ZS; Guan DK; Yang GW; Zhang GL
    Cancer Med; 2020 Jan; 9(1):179-193. PubMed ID: 31724326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer.
    Low YS; Blöcker C; McPherson JR; Tang SA; Cheng YY; Wong JYS; Chua C; Lim TKH; Tang CL; Chew MH; Tan P; Tan IB; Rozen SG; Cheah PY
    Cancer Lett; 2017 Sep; 403():13-20. PubMed ID: 28624625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative analysis from multi-centre studies identifies a function-derived personalized multi-gene signature of outcome in colorectal cancer.
    Sun J; Zhao H; Lin S; Bao S; Zhang Y; Su J; Zhou M
    J Cell Mol Med; 2019 Aug; 23(8):5270-5281. PubMed ID: 31140730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
    Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
    FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Prognostic Gene Signatures by Developing a scRNA-Seq-Based Integration Approach to Predict Recurrence and Chemotherapy Benefit in Stage II-III Colorectal Cancer.
    Wang Z; Xing K; Zhang B; Zhang Y; Chai T; Geng J; Qin X; Zhang X; Xu C
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA.
    Wan N; Weinberg D; Liu TY; Niehaus K; Ariazi EA; Delubac D; Kannan A; White B; Bailey M; Bertin M; Boley N; Bowen D; Cregg J; Drake AM; Ennis R; Fransen S; Gafni E; Hansen L; Liu Y; Otte GL; Pecson J; Rice B; Sanderson GE; Sharma A; St John J; Tang C; Tzou A; Young L; Putcha G; Haque IS
    BMC Cancer; 2019 Aug; 19(1):832. PubMed ID: 31443703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer.
    O'Cathail SM; Wu CH; Lewis A; Holmes C; Hawkins MA; Maughan T
    Cancer Genet; 2020 Oct; 248-249():1-10. PubMed ID: 32871287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and Clinical Validation of a Novel 4 Gene-Signature with Prognostic Utility in Colorectal Cancer.
    Ahluwalia P; Mondal AK; Bloomer C; Fulzele S; Jones K; Ananth S; Gahlay GK; Heneidi S; Rojiani AM; Kota V; Kolhe R
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients.
    Sveen A; Ågesen TH; Nesbakken A; Meling GI; Rognum TO; Liestøl K; Skotheim RI; Lothe RA
    Clin Cancer Res; 2012 Nov; 18(21):6001-10. PubMed ID: 22991413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.
    Dunne PD; O'Reilly PG; Coleman HG; Gray RT; Longley DB; Johnston PG; Salto-Tellez M; Lawler M; McArt DG
    Oncotarget; 2016 Jun; 7(24):36632-36644. PubMed ID: 27153559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.